MRK
Merck & Co., Inc.
NYSE · Healthcare · Drug Manufacturers - General · US
$150.67
−1.10%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
17.5x
EV/EBITDA
30.2x
Market Cap
$371.73B
MomentumView details →
1D Return
−1.10%
YTD Return
+44.42%
RSI (14)
66.2
ValuationView details →
P/E (Fwd)
17.5x
EV/EBITDA
30.2x
Market Cap
$371.73B
RSI (14)
66.2
MomentumView details →
1D Return
−1.10%
YTD Return
+44.42%
SummaryUpdated Jun 1, 2026
Merck & Co., Inc. (NYSE:MRK) is one of the world's largest pharmaceutical companies, founded in 1891 and headquartered in Kenilworth, New Jersey. Originally established as the American subsidiary of the German chemical company E. Merck, the company became independent during World War I and has since evolved into a global healthcare leader. Today, Merck operates as a diversified healthcare company serving patients worldwide through two primary business segments: pharmaceuticals for human health and animal health products. The company has built its reputation on developing breakthrough medicines and vaccines that address some of the most challenging diseases facing humanity.
Similar companies
Latest newsMore news →
Merck announced that China's National Medical Products Administration approved its PD-1 inhibitor Keytruda (pembrolizumab) for the neoadjuvant and adjuvant treatment of resectable locally advanced head and neck squamous cell carcinoma in adult patients with PD-L1 expression (CPS ≥1).16h agoElectroninks, Merck, and Qualipoly Chemical formed a strategic partnership to build an advanced packaging ecosystem for semiconductor customers.16h ago